A recent study using a genetically engineered mouse model confirmed the oncogenic effect of EZH2 and showed that overexpression of EZH2 resulted in aberrant spread of H3K27me3 at the known tumor suppressors in lung cancer, thus pointing to EZH2 as a pressing target for cancer therapy (Zhang et al., 2016). This evidence concerns the gene EZH2 and cancer.